Lewis Joshua R, Lim Wai H, Ueland Thor, Wong Germaine, Zhu Kun, Lim Ee M, Bollerslev Jens, Prince Richard L
University of Western Australia School of Medicine and Pharmacology, Sir Charles Gairdner Hospital Unit, Perth, Australia; Department of Endocrinology and Diabetes, Sir Charles Gairdner Hospital, Perth, Australia.
University of Western Australia School of Medicine and Pharmacology, Sir Charles Gairdner Hospital Unit, Perth, Australia; Department of Renal Medicine, Sir Charles Gairdner Hospital, Perth, Australia.
PLoS One. 2015 Jul 29;10(7):e0134266. doi: 10.1371/journal.pone.0134266. eCollection 2015.
Data on the predictive role of estimated glomerular filtration rate (eGFR) and osteoprotegerin (OPG) for cardiovascular (CVD) and all-cause mortality risk have been presented by our group and others. We now present data on the interactions between OPG with stage I to III chronic kidney disease (CKD) for all-cause and CVD mortality.
The setting was a 15-year study of 1,292 women over 70 years of age initially randomized to a 5-year controlled trial of 1.2 g of calcium daily. Serum OPG and creatinine levels with complete mortality records obtained from the Western Australian Data Linkage System were available. Interactions were detected between OPG levels and eGFR for both CVD and all-cause mortality (P < 0.05). Compared to participants with eGFR ≥60 ml/min/1.73 m2 and low OPG, participants with eGFR of <60 ml/min/1.73 m2 and elevated OPG had a 61% and 75% increased risk of all-cause and CVD mortality respectively (multivariate-adjusted HR, 1.61; 95% CI, 1.27-2.05; P < 0.001 and HR, 1.75; 95% CI, 1.22-2.55; P = 0.003). This relationship with mortality was independent of decline in renal function (P<0.05). Specific causes of death in individuals with elevated OPG and stage III CKD highlighted an excess of coronary heart disease, renal failure and chronic obstructive pulmonary disease deaths (P < 0.05).
The association between elevated OPG levels with CVD and all-cause mortality was more evident in elderly women with poorer renal function. Assessment of OPG in the context of renal function may be important in studies investigating its relationship with all-cause and CVD mortality.
我们团队及其他研究团队已公布了关于估计肾小球滤过率(eGFR)和骨保护素(OPG)对心血管疾病(CVD)及全因死亡风险的预测作用的数据。我们现在展示OPG与Ⅰ至Ⅲ期慢性肾脏病(CKD)之间相互作用对全因和CVD死亡率影响的数据。
本研究为一项针对1292名70岁以上女性的为期15年的研究,这些女性最初被随机分配至一项为期5年的每日服用1.2克钙的对照试验。可获取来自西澳大利亚数据链接系统的血清OPG和肌酐水平以及完整的死亡率记录。检测到OPG水平与eGFR在CVD和全因死亡率方面均存在相互作用(P<0.05)。与eGFR≥60 ml/min/1.73 m²且OPG水平较低的参与者相比,eGFR<60 ml/min/1.73 m²且OPG水平升高的参与者全因死亡率和CVD死亡率分别增加61%和75%(多变量调整后的HR,1.61;95%CI,1.27 - 2.05;P<0.001;HR,1.75;95%CI,1.22 - 2.55;P = 0.003)。这种与死亡率的关系独立于肾功能下降(P<0.05)。OPG水平升高且处于Ⅲ期CKD的个体的特定死亡原因显示冠心病、肾衰竭和慢性阻塞性肺疾病死亡人数过多(P<0.05)。
OPG水平升高与CVD和全因死亡率之间的关联在肾功能较差的老年女性中更为明显。在研究OPG与全因和CVD死亡率的关系时,结合肾功能评估OPG可能很重要。